Results for this period
Interim period (second quarter)1 January 2026–30 June 2026ConsolidatedIFRSThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Growth in globally strategic products, mainly in North America and EMEA, higher technology income, a ¥12.6 billion positive impact on revenue from foreign exchange, higher gross profit, lower research and development expenses, and a ¥5.6 billion positive impact on core operating profit from foreign exchange.
No applicable matters.
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 January 2026–30 June 2026 |
| Net Sales | ¥263,629 million (YoY +14.3%) |
| Operating profit | ¥66,149 million (core operating profit) (YoY +79.6%) |
| Ordinary income | 37,465 Millions of yen (interim profit before tax) (YoY +70.5%) |
| Profit attributable to owners of the parent | ¥30,618 million (YoY +87.6%) |
| Net income per share | ¥58.48 |
| Equity ratio | End of the current fiscal period 81 / End of previous period 80.6 |
| Total assets | ¥1,130,944 million |
| Net assets | ¥916,165 million (total equity) |
| Cash flows from operating activities | ¥81,334 million |
| Cash flows from investing activities | ¥-17,555 million |
| Cash flows from financing activities | ¥-18,763 million |
| Cash and cash equivalents at end of period | ¥265,083 million |
| Full-year earnings forecast | Net Sales ¥520,000 million (YoY +4.7%) / Operating profit ¥130,000 million (core operating profit) (YoY +18.4%) / Ordinary income ¥95,000 million (profit before tax) (YoY +8.9%) / Net income 75,000 Millions of yen (profit for the period) (YoY +11.9%) |
| Revision to Earnings Forecast | None (no revision) |
| Annual Dividend Forecast | ¥62.00 → ¥70.00 |
| Regional sales | Japan ¥549 million (YoY -5.9%) / North America ¥1,033 million (YoY +16.8%) / EMEA ¥433 million (YoY +17.0%) / Other ¥621 million (YoY +32.5%) / Total revenue ¥2,636 million (YoY +14.3%) |
| Depreciation and amortization | ¥15,420 million (depreciation and amortization) |
| Impairment loss | ¥5,556 million |
| Disclosure regarding the going concern assumption | No applicable matters. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate Yes / Restatement Not disclosed |
| Changes in the scope of consolidation | New Not disclosed / Excluded Number of companies 1 / Company name Orchard Therapeutics Limited |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for institutional investors and securities analysts) |
| Issued Shares at Period-End | 525,634,500 Shares |
| Treasury Shares at Period-End | 2,048,889 Shares |
| Factors Behind Changes in Business Performance | Growth in globally strategic products, mainly in North America and EMEA, higher technology income, a ¥12.6 billion positive impact on revenue from foreign exchange, higher gross profit, lower research and development expenses, and a ¥5.6 billion positive impact on core operating profit from foreign exchange. |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue increased due to growth in globally strategic products, mainly in North America and EMEA, higher technology income, and foreign exchange effects. Core operating profit increased due to higher gross profit and lower research and development expenses.